Bjc Reports
Overview
Bjc Reports is a scientific journal, published by Nature Portfolio since 2022 in English. The journal's country of origin is United Kingdom.
Details
Details
Abbr.
BJC Rep
Publisher
Nature Portfolio
Start
2022
End
Continuing
e-ISSN
2731-9377
Country
United Kingdom
Language
English
Recent Articles
1.
Abdalla T, Ohan J, Ives A, White D, Choong C, Bulsara M, et al.
BJC Rep
. 2025 Mar;
3(1):15.
PMID: 40082620
Background: Childhood cancer survivors (CCS) experience an elevated burden of health complications, underscoring the importance of understanding the patterns of multimorbidity to guide the management of survivors with complex medical...
2.
Wang Y, Allen I, Funingana G, Tischkowitz M, Joko-Fru Y
BJC Rep
. 2025 Mar;
3(1):14.
PMID: 40069561
Background: PARP inhibitors are effective in treating ovarian cancer, especially for BRCA1/2 pathogenic variant carriers and those with HRD (homologous recombination deficiency). Concerns over toxicity and costs have led to...
3.
Westwood A, Wilson B, Laye J, Grabsch H, Mueller W, Magee D, et al.
BJC Rep
. 2025 Mar;
3(1):12.
PMID: 40033106
Background: Within the colorectal cancer (CRC) tumour microenvironment, tumour infiltrating lymphocytes (TILs) and tumour cell density (TCD) are recognised prognostic markers. Measurement of TILs and TCD using deep-learning (DL) on...
4.
Mysko C, Landi S, Purssell H, Allen A, Prince M, Lindsay G, et al.
BJC Rep
. 2025 Mar;
3(1):13.
PMID: 40033086
Background: Hepatocellular carcinoma (HCC) remains a deadly cancer in the UK despite advancements in curative therapies. Societal conditions and health inequalities influence the development of chronic liver disease and outcomes...
5.
Hecht J, Michot J, Bajor D, Patnaik A, Chung K, Wang J, et al.
BJC Rep
. 2025 Feb;
3(1):10.
PMID: 40016550
Background: Dual programmed cell death protein (ligand)-1 (PD-[L]1) and lymphocyte-activation gene-3 (LAG-3) blockade has demonstrated improved anti-tumour response in some advanced solid tumours. CITRINO, a two-part, Phase 1 dose-escalation study,...
6.
Jokinen V, Taira A, Kolterud A, Ahlgren I, Palin K, Katainen R, et al.
BJC Rep
. 2025 Feb;
3(1):9.
PMID: 40016412
Background: Fibroblast growth factor 1-4 (FGFR1-4) are well-known oncogenic drivers in many cancer types. Here, we studied the role of FGFRs in uterine leiomyoma (UL) that is a benign neoplasm...
7.
Ingham J, Ruan J, Coelho M
BJC Rep
. 2025 Feb;
3(1):11.
PMID: 40016372
Most cancer-related deaths result from drug-resistant disease(1,2). However, cancer drug resistance is not a primary focus in drug development. Effectively mitigating and treating drug-resistant cancer will require advancements in multiple...
8.
Aro K, Loukovaara M, Butzow R, Pasanen A
BJC Rep
. 2025 Feb;
3(1):8.
PMID: 39939712
Background: Emerging HER2-targeted therapies provide new treatment options for patients with HER2-expressing tumors. This study investigates the prevalence of HER2 amplification and HER2 low expression across a well-characterized cohort of...
9.
Dolan R, Pennel K, Thompson J, McKenzie M, Alexander P, Richards C, et al.
BJC Rep
. 2025 Feb;
3(1):7.
PMID: 39910331
Background: In cancer cachexia the relationship between the tumour, its environment and the systemic inflammatory response is not clear. This study aims to examine this relationship in greater detail. Methods:...
10.
Omary R
BJC Rep
. 2025 Jan;
3(1):6.
PMID: 39870935
The author transitions his career in oncology to one in planetary health. The career pivot begins after he recognizes similarities between the pandemic and the climate crisis. The author determines...